🇺🇸 FDA
Patent

US 10251938

Angiopoietin-based interventions for treating cerebral malaria

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 10251938 (Angiopoietin-based interventions for treating cerebral malaria) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/357